reports
Dapirolizumab Pegol Phase 3 Data Presented at the American College of ...
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease activityA greater response was observed across multiple clinical endpoints among participants treated with DZP including 50% less severe disease flares compared to participants on standard of care aloneSystemic Lupus Erythematosus is a chron...
- Amira Manai
- Jerôme Bodin
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
APAML APERAM SA
EVT EVOTEC SE
GBF BILFINGER SE
SCR SCOR SE
BLC BASTIDE LE CONFORT MEDICAL SA
PSM PROSIEBENSAT.1 MEDIA SE
BRBY BURBERRY GROUP PLC
ENI ENI S.P.A.
MBB MBB INDUSTRIES SE
XIOR XIOR STUDENT HOUSING N.V.
REP REPSOL SA
ERG ERG S.P.A.
CARM CARMILA SAS
LTA ALTAMIR ACT PORTEUR
RENE REDES ENERGETICAS NACIONAIS SA
COL INMOBILIARIA COLONIAL SOCIMI SA
BP. BP P.L.C.
DMP DERMAPHARM HOLDING SE
CAF CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
S92 SMA SOLAR TECHNOLOGY AG
VK VALLOUREC SA
NA9 NAGARRO
AERO MONTANA AEROSPACE AG
MRX MISTER SPEX SE
NVM NOVEM GROUP SA
SHEL SHELL PLC
CO CASINO GUICHARD-PERRACHON
- Amira Manai
- Jerôme Bodin
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
APAML APERAM SA
EVT EVOTEC SE
GBF BILFINGER SE
SCR SCOR SE
BLC BASTIDE LE CONFORT MEDICAL SA
PSM PROSIEBENSAT.1 MEDIA SE
BRBY BURBERRY GROUP PLC
ENI ENI S.P.A.
MBB MBB INDUSTRIES SE
XIOR XIOR STUDENT HOUSING N.V.
REP REPSOL SA
ERG ERG S.P.A.
CARM CARMILA SAS
LTA ALTAMIR ACT PORTEUR
RENE REDES ENERGETICAS NACIONAIS SA
COL INMOBILIARIA COLONIAL SOCIMI SA
BP. BP P.L.C.
DMP DERMAPHARM HOLDING SE
CAF CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
S92 SMA SOLAR TECHNOLOGY AG
VK VALLOUREC SA
NA9 NAGARRO
AERO MONTANA AEROSPACE AG
MRX MISTER SPEX SE
NVM NOVEM GROUP SA
SHEL SHELL PLC
CO CASINO GUICHARD-PERRACHON
- Oliver Metzger
- Stephan Wulf
Evotec SE : Halozyme confirmed a non-binding € 2bn offer – Looks attra...
>Halozyme sees a good fit for both of Evotec’s business units - Halozyme Therapeutics, Inc. confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE to acquire Evotec for € 11.00 per share in cash, implying a fully diluted equity value of € 2.0bn. The proposal represents a premium of 27% to yesterday’s closing price and a premium of 77% to Evotec's last three-month volume weighted average price on 15 October 2024, th...
- Dylan Shindler
- Laura Chico
Eisai Receives Positive Opinion from the CHMP in the European Union fo...
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of the amyloid-beta (Aβ) monoclonal antibody lecanemab as...
- Dylan Shindler
- Laura Chico
Lonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufa...
Lonza Group AG / Key word(s): Expansion Lonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufacturing Suites 12.11.2024 / 07:00 CET/CEST The expansion of bioconjugation capabilities will provide additional manufacturing capacity for launch and commercial supply, addressing growing market demand 2,000m2 of manufacturing space will include two additional production suites and supporting infrastructure A significant increase in bioconjugation capacity will enable Lonza to offer expertise to a broad customer base and address the expected increase in approvals Basel, S...
- Thomas J. Schiessle
Management erwartet Trendwende ab Q4/24; „Priority Reset“ = Fokussieru...
Die Trendwende deutet sich an. Die Q3-KPIs zeigen erste Umsatz- und Margen-Erholung, denn Kapazitäten steigen und die „Reset“-Sanierungen beginnt Früchte zu tragen (Q3/24: Umsatz €185 +1,5%; EPS € -0,22 (Q3/23: € -0,22)). Der Liquiditätsabfluss ist in Q3 gestoppt. Doch die allgemeine Orderentwicklung ist noch von Zurückhaltung geprägt. Q4/24 soll (projektgetrieben) ein starkes Quartal (inkl. Reset-Einsparungen) werden - die 24er Guidance wird bestätigt.
- Wedbush Research
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
TSLA TESLA INC
TRNO TERRENO REALTY CORPORATION
STKS ONE GROUP HOSPITALITY
STAG STAG INDUSTRIAL INC.
O REALTY INCOME CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
BPMC BLUEPRINT MEDICINES CORP.
BIIB BIOGEN INC.
AZO AUTOZONE INC.
AAP ADVANCE AUTO PARTS INC.
ORLY O'REILLY AUTOMOTIVE INC.
PLYM PLYMOUTH INDUSTRIAL REIT INC.
MRSN MERSANA THERAPEUTICS
OVID OVID THERAPEUTICS
AAPL APPLE INC.
SRRK SCHOLAR ROCK HOLDING CORPORATION
EPRT ESSENTIAL PROPERTIES REALTY TRUST
PINS PINTEREST INC. CLASS A
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
VOR VOR BIOPHARMA
TCRX TSCAN THERAPEUTICS INC
UWMC UWM HLDGS CORP
NTST NETSTREIT CORP
BNL BROADSTONE NET LEASE INC
- Ritika Das
- Robert Driscoll
- Sam Ravina
- Wedbush Research
GEO GEO GROUP INC. (THE)
XENE XENON PHARMACEUTICALS INC
WING WINGSTOP INC.
TSLA TESLA INC
SAGE SAGE THERAPEUTICS INC.
RNG RINGCENTRAL INC. CLASS A
PZZA PAPA JOHN'S INTERNATIONAL INC.
NBIX NEUROCRINE BIOSCIENCES INC.
LOW LOWE'S COMPANIES INC.
KURA KURA ONCOLOGY INC.
HD HOME DEPOT INC.
GOOGL ALPHABET INC. CLASS A
FTNT FORTINET INC.
EXPE EXPEDIA GROUP INC.
CXW CORECIVIC INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
PTGX PROTAGONIST THERAPEUTICS
RDFN REDFIN CORPORATION
AMZN AMAZON.COM INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
BKNG BOOKING HOLDINGS INC.
HEAR TURTLE BEACH CORP.
RH RESTORATION HARDWARE INC.
PINS PINTEREST INC. CLASS A
GOSS GOSSAMER BIO
STOK STOKE THERAPEUTICS
DT DYNATRACE INC.
DDOG DATADOG INC CLASS A
APRE APREA THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
U UNITY SOFTWARE
RZLT REZOLUTE
ABNB AIRBNB INC. CLASS A
PLTR PALANTIR TECHNOLOGIES
VOR VOR BIOPHARMA
BUR BURFORD CAPITAL
CGEM CULLINAN ONCOLOGY INC
UPST UPSTART HOLDINGS
LBPH LONGBOARD PHARMACEUTICALS
VERA VERA THERAPEUTICS INC
TTD THE TRADE DESK
GLUE INC.
ARHS MONTE ROSA THERAPEUTICS INC
CCSI ARHAUS INC
RIVN CONSENSUS CLOUD SOLUTIONS INC
VIGL RIVIAN AUTOMOTIVE INC
PEPG VIGIL NEUROSCIENCE INC
TOST PEPGEN INC
EWTX TOAST INC
GETY EDGEWISE THERAPEUTICS INC
SKLZ GETTY IMAGES HOLDINGS INC
DNTH SKILLZ INC
CRBP DIANTHUS THERAPEUTICS INC
SYRE CORBUS PHARMACEUTICALS HOLDINGS INC.
SPYRE THERAPEUTICS INC.
- Dylan Shindler
- Laura Chico
- Emira Sagaama
- Juan Ros-Padilla
AMS AMS AG
CRI CHARGEURS SA
EVT EVOTEC SE
FLY SOCIETE FONCIERE LYONNAISE SA
LXS LANXESS AG
BEN BENETEAU SA
KCO KLOECKNER & CO SE
VLS VALNEVA SE
JCQ JACQUET METALS SA
ELG ELMOS SEMICONDUCTOR SE
BAMNB KONINKLIJKE BAM GROEP NV
WIZZ WIZZ AIR HOLDINGS PLC
GN GN STORE NORD A/S
GLB GLANBIA PLC
DEZ DEUTZ AG
AALB AALBERTS N.V.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
FDR FLUIDRA S.A.
CPINV CARE PROPERTY INVEST SA
LOG COMPANIA DE DISTRIBUCION INTEGRAL LOGISTA HOLDINGS S.A.
TWEKA TKH GROUP N.V. CERT
SMHN SUESS MICROTEC AG
DIC DIC ASSET AG
ALFEN ALFEN NV
INS INSTONE REAL ESTATE GROUP AG
HAG HENSOLDT AG
COP COMPUGROUP MEDICAL SE & CO. KGAA
KTA KNAUS TABBERT
RWI RENEWI PLC
HGEA HGEARS AG
AF AIR FRANCE - KLM
- Emira Sagaama
- Juan Ros-Padilla
AMS AMS AG
CRI CHARGEURS SA
EVT EVOTEC SE
FLY SOCIETE FONCIERE LYONNAISE SA
LXS LANXESS AG
BEN BENETEAU SA
KCO KLOECKNER & CO SE
VLS VALNEVA SE
JCQ JACQUET METALS SA
ELG ELMOS SEMICONDUCTOR SE
BAMNB KONINKLIJKE BAM GROEP NV
WIZZ WIZZ AIR HOLDINGS PLC
GN GN STORE NORD A/S
GLB GLANBIA PLC
DEZ DEUTZ AG
AALB AALBERTS N.V.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
FDR FLUIDRA S.A.
CPINV CARE PROPERTY INVEST SA
LOG COMPANIA DE DISTRIBUCION INTEGRAL LOGISTA HOLDINGS S.A.
TWEKA TKH GROUP N.V. CERT
SMHN SUESS MICROTEC AG
DIC DIC ASSET AG
ALFEN ALFEN NV
INS INSTONE REAL ESTATE GROUP AG
HAG HENSOLDT AG
COP COMPUGROUP MEDICAL SE & CO. KGAA
KTA KNAUS TABBERT
RWI RENEWI PLC
HGEA HGEARS AG
AF AIR FRANCE - KLM
- Oliver Metzger
- Stephan Wulf
Evotec SE : In its CC Evotec predicts strong Q4 – but we see no attrac...
>Evotec is confident about a strong Q4 to meet FY guidance - The company appeared quite confident in achieving its 2024 EBITDA guidance of € 15-35m, which requires at least a Q4 adj. EBITDA of € 21.8m after a loss of -€ 6m after nine months. Evotec sees three main drivers for a strong Q4: 1/ a significant increase in sales, which is covered by the current orderbook, this will strongly translate into EBITDA due to high operating leverage, 2/ further cost optimisation w...
- Olfa Taamallah
- Thomas Zlowodzki
- Yan Derocles
ODDO BHF Small & MIDCAP MORNING NEWS - 06/11/2024
Notre scénario central s’est concrétisé dans la nuit : Donald Trump remporte la présidentielle américaine, et le choix des électeurs ne devrait pas être contesté. Il pourrait disposer d’une majorité dans les deux assemblées. Les actions américaines en seront les premières bénéficiaires. Sur les actions européennes, les secteurs les plus gagnants seront l’Energie, les Médias, les Métaux, Construction & Materials, Financial Services, Insurance. Sont en revanche plus à risque Utilities, ...
- Olfa Taamallah
- Thomas Zlowodzki
- Yan Derocles
ODDO BHF Small & MIDCAP MORNING NEWS - 11/06/2024
Our baseline scenario materialised last night: Donald Trump seems to be on course to win the US presidential election, and the choice of the electorate is unlikely to be challenged. He could end up with a majority in both houses of Congress. US equities will be the first to benefit from this development. In European equities, the biggest winners will be Energy, Media, Metals, Construction & Materials, Financial Services and Insurance. More at risk, however, are the Utilities, Spirits,...
- Oliver Metzger
- Stephan Wulf
Evotec SE : Operating challenges remain as cash burn stopped in Q3
>Group’s Q3 sales in line – slight miss at the EBITDA line - Evotec’s 9M results came in slightly below expectations. 9M 2024 sales of € 575m (-1%%) were in line with our (€ 576m) and 1% below the consensus estimates (€ 582m). The group’s gross profit of € 68.8m (-50%) is 1.4% below our estimates and 5.4% below the consensus. Adj. EBITDA posted a loss of -€ 6m vs a profit of € 50.2m after nine months in 2023. This compares with our estimate of -€ 4.9m and the consensu...
EQS-News: Evotec SE reports 9M 2024 results: Strategic Progress and Su...
EQS-News: Evotec SE / Key word(s): 9 Month figures Evotec SE reports 9M 2024 results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions 06.11.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditions Robust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnerships Successful extensions & expansions with BMS an...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.